U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H14N8O2
Molecular Weight 314.3027
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOLIDUSTAT

SMILES

O=C1N(NC=C1N2C=CN=N2)C3=NC=NC(=C3)N4CCOCC4

InChI

InChIKey=IJMBOKOTALXLKS-UHFFFAOYSA-N
InChI=1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2

HIDE SMILES / InChI

Molecular Formula C13H14N8O2
Molecular Weight 314.3027
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molidustat also was known as BAY 85-3934 is a novel inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) which stimulates erythropoietin (EPO) production and the formation of red blood cells. Hypoxia-inducible factor (HIF) is the major transcription factor involved in erythropoietin gene expression. Because oxygen-dependent degradation of the α subunit of HIF suppresses erythropoietin expression, stimulation of erythropoiesis by agents that prevent degradation of HIF has been one strategy for managing anemia. Thus, molidustat is in phase II of a clinical trial to investigate the effects therapy in patients with renal anemia associated with chronic kidney disease and/or end-stage renal disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Targeting the hypoxia-sensing pathway in clinical hematology.
2014 Feb
Patents

Sample Use Guides

Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
Route of Administration: Oral
BAY 85-3934 (molidustat) induced the transcription of hypoxia-sensitive genes in HeLa, A549, and Hep3B cells. The mRNA expression levels of a panel of HIF target genes were analyzed by quantitative RT-PCR (qRT-PCR) in the three cell lines 4 h after exposure to concentrations of BAY 85-3934 up to 10 µM. mRNA levels were found to be induced by BAY 85-3934 in a dose-dependent manner. The basal level of expression and the factor of induction varied considerably between cell lines. The highest induction factors (up to 20-fold) were observed for carbonic anhydrase IX (CA-IX) in HeLa cells, CA-IX and angiopoietin-like 4 (ANGPTL-4) in A549 cells, and EPO and ANGPTL-4 in Hep3B cells. The other genes examined were induced between 2- and 5-fold. The mRNA expression level of ANGPTL-4 was not increased by BAY 85-3934 in HeLa cells. EPO mRNA was not detectable at baseline and not induced in HeLa or A549 cells. The threshold concentration for induction of CA-IX expression was 500 nM in HeLa cells, and greater than 1 µM for all other genes that showed a response.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:32:50 UTC 2023
Edited
by admin
on Sat Dec 16 05:32:50 UTC 2023
Record UNII
9JH486CZ13
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOLIDUSTAT
INN   WHO-DD  
USAN   INN  
Official Name English
BAY-85-3934
Code English
3H-PYRAZOL-3-ONE, 1,2-DIHYDRO-2-(6-(4-MORPHOLINYL)-4-PYRIMIDINYL)-4-(1H-1,2,3-TRIAZOL-1-YL)-
Systematic Name English
Molidustat [WHO-DD]
Common Name English
MOLIDUSTAT [USAN]
Common Name English
molidustat [INN]
Common Name English
2-(6-(MORPHOLIN-4-YL)PYRIMIDIN-4-YL)-4-(1H-1,2,3-TRIAZOL-1-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE
Systematic Name English
Code System Code Type Description
PUBCHEM
59603622
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
SMS_ID
100000175261
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
EPA CompTox
DTXSID80151089
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
FDA UNII
9JH486CZ13
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
DRUG BANK
DB15642
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
CAS
1154028-82-6
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
WIKIPEDIA
Molidustat
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
USAN
JK-106
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
NCI_THESAURUS
C174580
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
INN
9655
Created by admin on Sat Dec 16 05:32:50 UTC 2023 , Edited by admin on Sat Dec 16 05:32:50 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY